Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation

Hyue Mee Kim¹,², Eue-Keun Choi¹*, Chan Soon Park¹, Myung-Jin Cha¹, Seo-Young Lee¹, Joon-Myung Kwon³, Seil Oh¹

¹ Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ² Division of Cardiology, Heart Stroke Vascular Center, Mediplex Sejong Hospital, Incheon, Republic of Korea, ³ Department of Emergency medicine, Mediplex Sejong Hospital, Incheon, Republic of Korea

* choiek17@snu.ac.kr

Abstract

Background and objective

Elderly patients with atrial fibrillation (AF) are known to have a high risk of stroke and bleeding. We investigated the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in octogenarian patients with non-valvular AF compared with warfarin.

Methods

A total of 687 octogenarian patients with AF who were administered NOACs (n = 403) or warfarin (n = 284) for stroke prevention between 2012 and 2016 were included. Thromboembolic (TE) events (stroke or systemic embolism), major bleeding events, and all-cause death were analyzed.

Results

The NOACs group (age 83.4±3.2 years, women 52.4%, CHA²DS²-VASc score 5.0±1.8) comprised 141 dabigatran, 158 rivaroxaban, and 104 apixaban users. Most patients from the NOACs group had been prescribed a reduced dose of medication (85.6%). During 14±18 months of follow-up periods, there were 19 TE events and 18 major bleeding events. Patients with NOAC showed a lower risk of TE (1.84 vs. 2.71 per 100 person-years, hazard ratio [HR] 0.134, 95% confidence interval [CI] 0.038–0.479, P = 0.002), major bleeding (1.48 vs. 2.72 per 100 person-years, HR 0.110, 95% CI 0.024–0.493, P = 0.001), and all-cause death (2.57 vs. 3.50 per 100 person-years, HR 0.298, 95% CI 0.108–0.824, P = 0.020).

Conclusion

In octogenarian Asian patients with AF, NOACs might be associated with lower risks of thromboembolic events, major bleeding, and all-cause death than warfarin. Although most patients had received reduced doses, on-label use of NOACs was effective and safe.
Introduction

Atrial fibrillation (AF) is the most common arrhythmia observed in elderly patients, and one of the major causes of stroke in this population. The prevalence and incidence of AF in patients at a very advanced age (≥80 years) has shown a significant increase in Asians.[1,2] With the aging of the general population, the burden of AF and its complications has also been increasing. Elderly patients with AF are at an increased risk of both stroke and major bleeding. Although anticoagulation therapy using vitamin K antagonists reduces the risk of stroke in the elderly patients, warfarin has shown an increased risk of bleeding in the elderly population.[3,4] Additionally, warfarin use is associated with several limitations in elderly patients for the risk of cognitive impairment, poor medication adherence, and a narrow therapeutic range.[5–8] These limitations have been partly controlled by the introduction of non-vitamin K antagonist oral anticoagulants (NOACs), which have demonstrated comparable results in terms of stroke prevention and better safety outcomes in reducing the risk of major bleeding.[9–12]

Recently, we reported the effectiveness and safety of NOACs in Asian patients with AF and showed that NOACs when compared to warfarin are associated with a comparable risk of stroke and a lower risk of bleeding and all-cause death.[13] However, there is a still lack of data regarding NOACs effectiveness and safety in patients at a very advanced age (≥80 years), particularly among Asians. Elderly patients (those in the 9th decade) usually show a greater number of comorbidities and concomitant medication use, as well as a higher prevalence of impaired renal function than that observed in younger patients. Thus, effective and safe anticoagulation in octogenarian patients with AF is a critical issue. In this study, we sought to investigate the effectiveness and safety of NOACs in a real-world octogenarian patients with non-valvular AF.

Methods

Study population

We retrospectively analyzed a database of consecutive patients diagnosed with non-valvular AF who were older than 80 years old receiving warfarin or NOACs (dabigatran, rivaroxaban, and apixaban) at Seoul National University Hospital between January 2012 and June 2016. We focused on patients with non-valvular AF by excluding patients with rheumatic mitral valve disease or surgery for valve diseases. Patients were excluded if they had other diseases necessitating warfarin administration such as pulmonary embolism and deep vein thrombosis. After excluding 157 patients who were taking anticoagulants for conditions other than AF, 687 patients were deemed eligible for this study. Enrolled patients were divided into 2 groups: 403 patients were classified into the NOACs and 284 were classified into the warfarin group. Patients were assigned to each group when they received NOACs or warfarin for more than 1 day. Patients were censored when anticoagulant was changed to another or discontinued.

Using drug labeling (S1 Table) as a guide for classification, patients administered NOACs were categorized based on those who received the on-label recommended dose, those who were prescribed with off-label NOACs (under-dosed or over-dosed). Clinical data regarding baseline characteristics were retrieved from patients’ medical records. The risk factors for thromboembolism were evaluated using the CHADS2 and the CHA2DS2-VASc score. Among the laboratory tests performed, serum levels of blood urea nitrogen, creatinine, and hemoglobin were measured at the time of enrollment. The estimated glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease formula.[14] Our study was approved by the Seoul National University Hospital Institutional Review Board (1604-073-754) and was
conducted in accordance with the Declaration of Helsinki. This study was retrospective cohort study, thus the informed consent was waived by the ethics committee.

### Study outcomes

Patients were followed in outpatient clinics, and their clinical records were reviewed. In the warfarin group, anticoagulation control was assessed using the time in therapeutic range (TTR), which was assessed by Rosendaal method.[15] The primary outcomes evaluating effectiveness and safety were the occurrence of ischemic stroke and/or systemic embolism and major bleeding, respectively. Major bleeding was defined as bleeding needed transfusion of at least 2 units of red blood cells, a drop in hemoglobin more than 2g/L, a surgical revision required due to bleeding, bleeding into critical sites (intracranial, intra-ocular, intra-articular, retroperitoneal, and overt gastrointestinal (GI) bleeding), or fatal bleeding. We also included all-cause deaths as an endpoint.

### Statistical analysis

Continuous variables were expressed as mean ± SD and categorical variables as percentages. A 2-sided P value < 0.05 was considered statistically significant. Patient characteristics were compared between groups using a chi-squared test for categorical variables and the Student’s t test for continuous variables. Event rates were estimated using event counts and exposure following time. Univariate Cox proportional hazard regression analyses were performed to evaluate the predictive values of each variable, and variables observed to be significant were subjected to multivariable Cox proportional hazard regression model. We used stepwise backward elimination to select factors for inclusion in the multivariable analysis (inclusion criteria, P < 0.05; exclusion criteria, P > 0.1) because of the relatively small number of events (S2 Table). The hazard ratio (HR) and 95% confidence interval (CI) were calculated. Event-free survival analyses were conducted by Kaplan–Meier method with log-rank test and the Cox proportional hazard model. To estimate the effectiveness and safety of NOACs in the presence of confounding factors, weighted Kaplan-Meier analysis using inverse probability treatment weighting (IPTW) was performed. IPTW was based on the propensity score calculated with variables including age, sex, hypertension, diabetes mellitus, congestive heart failure, vascular disease, and stroke. All analyses were performed using the IBM SPSS statistics version 22 software (SPSS Inc., Chicago, IL, USA) and R version 3.4.3. (R Foundation for Statistical Computing).

### Results

#### Baseline characteristics

The baseline demographic characteristics of all groups of patients are depicted in Table 1. A total of 687 patients were included in this study. 403 patients were administered NOACs and 284 were administered. The mean age was 83.4±3.1 years and 345 (50.2%) of the patients were women. No statistically significant differences were observed in terms of age, sex, and body mass index (BMI). The patients in the NOACs group showed higher CHADS score (2.8±1.3 vs. 2.0±0.8) and CHA2DS2-VASc score (5.0±1.8 vs. 3.5±1.0) and higher prevalence of comorbidities such as congestive heart failure (21.1% vs. 4.2%) previous stroke (35.2% vs. 8.8%). Patients from both groups contributed 786 patient-years of on-therapy follow-up. The median follow-up duration was 7.8 months (inter-quartile range [IQR]: 2.5–19.3 months), 5.5 months (IQR 1.8–8.9 months) for the NOACs and 15.3 months (IQR 4.0–42.6 months) for the warfarin group. The mean TTR of the warfarin group was 49%.
During the follow-up, stroke or systemic embolic events were observed in 19 patients, and major bleeding events in 18. Fig 1 summarizes the clinical outcomes based on the treatment group. The overall incidence rate of thromboembolic events (TE) was 2.41 per 100 person-years. The overall incidence of major bleeding, GI bleeding, and intracranial hemorrhage (ICH) was 2.29, 1.15, and 0.76 per 100 person-years, respectively.

A comparison between the NOACs and warfarin groups showed statistically significant differences in TE and major bleeding events and all-cause deaths after adjusting for potential confounders (Fig 2). Stroke or systemic embolism occurred in 5 patients in the NOACs and 14 patients in the warfarin group. In univariate comparisons, there was no significant difference in TE events between NOACs and warfarin group (HR 0.468, 95% CI 0.163–1.344, P = 0.158). After adjusting for multiple variables including age, sex, previous history of hypertension, diabetes, congestive heart failure, vascular disease, and previous stroke, the NOACs group showed

### Table 1. Baseline characteristics.

|                      | NOACs (n = 403) | WFR (n = 284) | P value † |
|----------------------|-----------------|---------------|-----------|
| Age, yrs             | 83.4±3.2        | 83.5±3.1      | 0.529     |
| Female (%)           | 211 (52.4%)     | 134 (47.2%)   | 0.182     |
| Height, cm           | 157.8±14.1      | 158.7±12.0    | 0.847     |
| Body weight, kg      | 60.2±14.3       | 58.7±11.6     | 0.392     |
| BMI (Kg/m²)          | 24.7±14.4       | 23.6±9.0      | 0.326     |
| Past medical history |                 |               |           |
| Hypertension         | 246 (61.0%)     | 164 (57.7%)   | 0.386     |
| Diabetes mellitus    | 124 (30.8%)     | 80 (28.2%)    | 0.463     |
| Congestive heart failure | 85 (21.1%) | 12 (4.2%)     | <0.001    |
| Previous stroke      | 142 (35.2%)     | 25 (8.8%)     | <0.001    |
| Dementia             | 39 (9.7%)       | 16 (5.6%)     | 0.054     |
| Lab                  |                 |               |           |
| Hemoglobin           | 12.9±1.7        | 12.9±1.9      | 0.706     |
| BUN                  | 18.9±7.7        | 21.0±9.8      | 0.007     |
| Creatinine           | 1.1±0.3         | 1.2±0.8       | 0.004     |
| GFR                  |                 |               |           |
| Normal (>80mL/min)   | 86 (24.7%)      | 49 (21.4%)    | 0.04      |
| Mild impairment (50-80mL/min) | 200 (57.5%) | 119 (52.0%)  | 0.04      |
| Moderate impairment (30-50mL/min) | 56 (16.1%) | 50 (21.8%)  | 0.04      |
| Severe impairment (≤30mL/min) | 6 (1.7%) | 11 (4.8%)  | 0.04      |
| CHADS₂ score         | 2.8±1.3         | 2.0±0.8       | <0.001    |
| CHA₂DS₂-VASc         | 5.0±1.8         | 3.5±1.0       | <0.001    |
| HAS-BLED score       | 2.5±1.0         | 2.6±1.0       | 0.115     |
| NOAC                 |                 |               |           |
| Regular dose         | 58 (14.4%)      | -             |           |
| Reduced dose         | 345 (85.6%)     | -             |           |
| Median F/U duration, months | 5.5 (1.8–8.9) | 15.3 (4.0–42.6) | <0.001 |

Values are presented as mean ± SD, as n (%), or median (interquartile range).
WFR = warfarin
†P value between NOACs and warfarin groups

https://doi.org/10.1371/journal.pone.0211766.t001

### Thromboembolic and major bleeding events and all-cause deaths

During the follow-up, stroke or systemic embolic events were observed in 19 patients, and major bleeding events in 18. Fig 1 summarizes the clinical outcomes based on the treatment group. The overall incidence rate of thromboembolic events (TE) was 2.41 per 100 person-years. The overall incidence of major bleeding, GI bleeding, and intracranial hemorrhage (ICH) was 2.29, 1.15, and 0.76 per 100 person-years, respectively.

A comparison between the NOACs and warfarin groups showed statistically significant differences in TE and major bleeding events and all-cause deaths after adjusting for potential confounders (Fig 2). Stroke or systemic embolism occurred in 5 patients in the NOACs and 14 patients in the warfarin group. In univariate comparisons, there was no significant difference in TE events between NOACs and warfarin group (HR 0.468, 95% CI 0.163–1.344, P = 0.158). After adjusting for multiple variables including age, sex, previous history of hypertension, diabetes, congestive heart failure, vascular disease, and previous stroke, the NOACs group showed
There were 14 major bleeding episodes in the warfarin and 4 in the NOACs group. Multivariate analysis showed that the NOACs demonstrated a lower risk of major bleeding events than that observed in the warfarin group (HR 0.110, 95% CI 0.024–0.493, P = 0.001, Fig 2B). Among the major bleeding events, GI bleeding was the most common type (50.0%). The risk of major GI bleeding was similar between the NOACs and the warfarin group (HR 0.374, 95% CI 0.047–2.949, P = 0.347). ICH occurred in 5 patients in the warfarin group, whereas there was only 1 event in the NOACs group. Multivariate analysis revealed that the NOACs demonstrated a lower risk of ICH than that observed in the warfarin group (HR 0.024, 95% CI 0.002–0.350, P = 0.006).

In addition, the weighted Kaplan-Meier analysis using IPTW consistently revealed lower risks of thromboembolism (HR 0.131, 95% CI 0.038–0.479, P = 0.002, Fig 2A). a lower risk of TE than that observed in the warfarin group (HR 0.134, 95% CI 0.038–0.479, P = 0.002, Fig 2A).

### Table 1: Clinical outcomes based on the treatment group

| Outcome          | No. of patients | NOACs (100 person-years) | WFR (100 person-years) | Hazard ratio* (95% CI) | P value |
|------------------|----------------|--------------------------|------------------------|------------------------|---------|
| Thromboembolism  | 687            | 5 (1.84)                 | 14 (2.71)              | 0.134 (0.038–0.479)    | 0.002   |
| Major bleeding   | 687            | 4 (1.48)                 | 14 (2.72)              | 0.110 (0.024–0.493)    | 0.001   |
| GI bleeding      | 687            | 3 (1.1)                  | 6 (1.17)               | 0.374 (0.047–2.949)    | 0.347   |
| ICH              | 687            | 1 (0.37)                 | 5 (0.97)               | 0.024 (0.002–0.350)    | 0.006   |
| All-cause death  | 687            | 7 (2.57)                 | 18 (3.50)              | 0.298 (0.108–0.824)    | 0.020   |

*Hazard ratios adjusted with age, sex, previous history of HTN, DM, CHF, vascular disease, and stroke history

https://doi.org/10.1371/journal.pone.0211766.g001

![Figure 1](https://doi.org/10.1371/journal.pone.0211766.g001)

**Fig 1. Clinical outcomes based on the treatment group.** Hazard ratio adjusted with age, sex, previous history of hypertension, diabetes mellitus, congestive heart failure, vascular disease and stroke history. NOAC, non-vitamin K antagonist oral anticoagulants; WFR, warfarin; GI, gastrointestinal; ICH, intracranial hemorrhage.

https://doi.org/10.1371/journal.pone.0211766.g001

There were 14 major bleeding episodes in the warfarin and 4 in the NOACs group. Multivariate analysis showed that the NOACs demonstrated a lower risk of major bleeding events than that observed in the warfarin group (HR 0.110, 95% CI 0.024–0.493, P = 0.001, Fig 2B). Among the major bleeding events, GI bleeding was the most common type (50.0%). The risk of major GI bleeding was similar between the NOACs and the warfarin group (HR 0.374, 95% CI 0.047–2.949, P = 0.347). ICH occurred in 5 patients in the warfarin group, whereas there was only 1 event in the NOACs group. Multivariate analysis revealed that the NOACs demonstrated a lower risk of ICH than that observed in the warfarin group (HR 0.024, 95% CI 0.002–0.350, P = 0.006).

In addition, the weighted Kaplan-Meier analysis using IPTW consistently revealed lower risks of thromboembolism (HR 0.131, 95% CI 0.046–0.371, P = 0.0023) and major bleeding (HR 0.259, 95% CI 0.062–1.087, P = 0.051) in the patients with NOACs (S1 Fig and S3 Table).

![Figure 2](https://doi.org/10.1371/journal.pone.0211766.g002)

**Fig 2. Risk-adjusted event-free survival according to the treatment.** Event-free survival curves are demonstrated according to the treatment, adjusted for age, sex, previous history of hypertension, diabetes mellitus, congestive heart failure, vascular disease and stroke history. A) Event-free survival curve for thromboembolism, B) Event-free survival curve for major bleeding, C) Event-free survival curve for all-cause death. NOAC, non-vitamin K antagonist oral anticoagulants; WFR, warfarin.

https://doi.org/10.1371/journal.pone.0211766.g002
Among patients in whom data regarding GFR were available, 76% showed more than mild chronic kidney disease (CKD). Two-thirds of TE events (11 of 17, 65%) and major bleeding events (10 of 17, 62.5%) occurred in those who have more than mild CKD. No TE and major bleeding event was observed in the NOACs group with moderate to severe CKD, whereas 3 TE and 4 major bleeding events were observed in the warfarin group with moderate to severe CKD. NOACs and warfarin did not demonstrate a statistically significant effect on the occurrence of TE and major bleeding events based on renal function (P for interaction = 0.579 and 0.288, respectively).

Eighteen patients died in the warfarin group and 7 in the NOACs group (3.5 per 100 person-years, vs. 2.57 per 100 person-years, respectively). All-cause deaths were also observed to be significantly lower in the NOACs group (HR 0.298, 95% CI 0.108–0.824, P = 0.020, Fig 2C). Among the patients who died, 4 died after TE and 3 after major bleeding events.

Clinical outcomes based on the types and doses of NOACs

Among the 403 patients in the NOACs group, 141 received dabigatran, 158 received rivaroxaban, and 104 received apixaban. Among the patients who developed TE events, 3 had received dabigatran, 1 had received rivaroxaban, and 1 had received apixaban, respectively (2.38 vs. 1.15 vs. 1.72 per 100 person-years, respectively). Among patients with major bleeding events in the NOACs group, 2 had been treated with dabigatran, 1 with rivaroxaban, and 1 with apixaban, respectively (1.60 vs. 1.15 vs. 1.72 per 100 person-years, respectively).

In this study, most of patients (n = 345, 85.6%) had been prescribed a reduced dose (128 patients received dabigatran at a dose of 110 mg twice daily, 36 patients received rivaroxaban at a dose of 10 mg daily, 88 patients received rivaroxaban at a dose of 15 mg daily, and 93 patients received apixaban at a dose of 2.5 mg twice daily). There was no significant difference between two groups except for renal dysfunction (S4 Table). All clinical events occurred in those prescribed reduced doses of NOACs. After adjusting for covariables, patients who received reduced doses of NOACs showed a lower risk of TE events (HR 0.151, 95% CI 0.042–0.548, P = 0.004), major bleeding events (HR 0.125, 95% CI 0.027–0.586, P = 0.008), and all-cause deaths (HR 0.277, 95% CI 0.089–0.865, P = 0.27) compared to those who received warfarin. Based on dosage recommendations, 240 (59.6%) patients were prescribed the recommended dose of NOACs, whereas 36.7% were categorized as under-dosed and 3.7% as over-dosed (Fig 3). Most patients administered dabigatran were prescribed the drug based on recommended dose, whereas 67% of patients administered rivaroxaban were categorized as under-dosed. When comparing the patient groups with on-label and off-label under-dosed NOACs separately, significantly lower incidence rates of TE (HR 0.158, 95% CI 0.040–0.627, P = 0.002) and major bleeding events (HR 0.169, 95% CI 0.034–0.833 P = 0.029) were observed in the on-label NOACs than that observed in the warfarin group (Fig 4). Moreover, the patients with off-label under-dosed NOACs use showed similar trend in TE, major bleeding and all-cause death compared with those with warfarin.

Discussion

The main findings of this study are: (1) NOACs showed a lower risk of TE, major bleeding, and all-cause deaths than that observed with warfarin in octogenarian patients with non-valvular AF, (2) when comparing between the on- and off-label use of NOACs, the former showed better effectiveness and safety compared with warfarin in octogenarian patients, and (3) most octogenarian patients with AF showed renal dysfunction, but the effectiveness and safety of NOACs showed results that were comparable to those observed with warfarin use in these patients.
Several studies have reported the safety and effectiveness of NOACs in elderly patients. Most of them have been subgroup analysis or meta-analysis of representative randomized clinical trials assessing these drugs. Table 2 summarizes the studies reporting the effectiveness and safety of NOACs in octogenarian patients with AF in a real-world setting.[16–21] A recent European study has reported that 3 NOACs mentioned in this study showed a similar risk of TE and major bleeding events compared to warfarin in patients aged more than 80

![Fig 3. Proportion of NOACs dosing according to label.](https://doi.org/10.1371/journal.pone.0211766.g003)

![Fig 4. Clinical outcomes according to dose of NOACs.](https://doi.org/10.1371/journal.pone.0211766.g004)

| Thromboembolism                  | NOACs (100 person-years) | WFR | Hazard ratio* (95% CI) | P value |
|----------------------------------|--------------------------|-----|------------------------|---------|
| On-label use                     | 4 (2.41)                 | 14 (2.72) | 0.158 (0.040-0.627) | 0.002   |
| Under-dosed use                  | 1 (1.08)                 | 14 (2.72) | 0.173 (0.021-1.455) | 0.106   |

| Major bleeding                   |                          |     |                       |         |
|----------------------------------|--------------------------|-----|------------------------|---------|
| On-label use                     | 3 (1.82)                 | 14 (2.72) | 0.169 (0.034-0.833) | 0.029   |
| Under-dosed use                  | 1 (1.08)                 | 14 (2.72) | 0.144 (0.017-1.205) | 0.074   |

| All-cause death                  |                          |     |                       |         |
|----------------------------------|--------------------------|-----|------------------------|---------|
| On-label use                     | 6 (3.59)                 | 18 (3.50) | 0.427 (0.146-1.243) | 0.119   |
| Under-dosed use                  | 1 (1.08)                 | 18 (3.50) | 0.126 (0.015-1.036) | 0.054   |

*Hazard ratios adjusted with age, sex, previous history of HTN, DM, CHF, vascular disease, and stroke history

![Fig 3](https://doi.org/10.1371/journal.pone.0211766.g003)

![Fig 4](https://doi.org/10.1371/journal.pone.0211766.g004)
In an elderly Asian elderly population, a few studies have reported the effectiveness and safety of NOACs in octogenarian patients with AF. However, the number of patients investigated in these previous studies involving Asian patients was inadequate to conclusively establish the difference between the role of NOACs and warfarin in stroke prevention and reduction in major bleeding events. We observed that NOACs showed better effectiveness in TE prevention and a reduced risk of major bleeding, particularly in ICH compared to that observed with warfarin in octogenarian patients with AF. Furthermore, there was mortality benefit in NOACs group compared to warfarin. In contrast to previous Asian studies, 3 NOACs (dabigatran, rivaroxaban, and apixaban) were included and analyzed in this study.

Although stroke prevention effect of NOACs in elderly patients have been reported to be comparable with that of warfarin, reports describing their effect on bleeding complications have been inconsistent. In major phase 3 clinical trials, although NOAC use was associated with a reduced risk of major bleeding events, particularly for ICH, the risk of GI bleeding was noted to be increased. A meta-analysis of randomized clinical trials showed that NOACs (including dabigatran, rivaroxaban, and apixaban) did not cause excessive bleeding in those aged >75 years. Additionally, both dabigatran and rivaroxaban showed similar bleeding event rates compared to warfarin in octogenarian patients with AF in a real-world retrospective study. However, Halvorsen et al. reported that apixaban was shown to be superior to warfarin with respect to bleeding complications in patients aged >80 years. They assessed the efficacy and safety of apixaban according to age as subgroup analysis performed in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. In the present study, patients treated with NOACs showed a lower risk of major bleeding events—ICH particularly was observed to be lower in the NOAC than the warfarin group, whereas the risk of GI bleeding was not statistically significantly different between the groups. The number of patients included in the study and the type of NOACs administered might explain the differences between studies in terms of outcomes.

Table 2. Comparisons of previous studies for the effectiveness and safety of NOACs in elderly patients compared with warfarin.

| Population | NOACs included in the study | Effectiveness (stroke prevention) | Safety | All-cause death |
|------------|-----------------------------|----------------------------------|--------|----------------|
| ≥75 years (subgroup, n = 5,678) European (40.3%), American (43.8%), Asian (16.0%) | Apixaban | Reduced | Reduced | Reduced risk of ICH | Similar |
| ≥75 years (subgroup, n = 6229) European (53%), American (32%), Asian (15%) | Ribaroxaban | Similar | Similar | Similar risks for ICH | Increased risk of GI bleeding |
| ≥65 years, n = 134,414 American | Dabigatran | Reduced | Reduced risk of ICH | Increased risk of GI bleeding | Reduced |
| ≥80 years, n = 293 Asian (Korea) | Dabigatran, Ribaroxaban | Similar | Similar | |
| ≥80 years, n = 571 Asian (China) | Dabigatran | Reduced | Similar risks for ICH | |
| ≥80 years (subgroup, n = 7152) European (Sweden) | Dabigatran, Rivaroxaban | Similar | Increased risk of GI bleeding in regular dose | Similar |
| ≥80 years, n = 687 Asian (Korea) | Dabigatran, Rivaroxaban, Apixaban | Reduced | Reduced risk of ICH | Similar risk of GI bleeding | Reduced |

https://doi.org/10.1371/journal.pone.0211766.t002
In a post hoc analysis of bleeding events, dabigatran and rivaroxaban showed a higher event rate of GI bleeding in patients administered NOACs. Dabigatran was reported to show an interaction with a patient’s age for major and extracranial bleeding, whereas the risk of intracranial bleeding was consistently lower compared to that of warfarin irrespective of age. However, this result was most pronounced in patients treated with dabigatran at a dose of 150 mg twice daily, whereas in those treated with a reduced dose (75 mg twice daily) the risk of major bleeding events was similar to that of warfarin except for a lower risk of ICH associated with dabigatran use. Rivaroxaban use did not show a statistically significant difference in the occurrence of major bleeding events; however, the risk of GI bleeding was higher, particularly among elderly patients.

It is known that in real-world clinical practice, octogenarian patients are expected to show a higher risk of bleeding events and therefore tend to be prescribed reduced-dose NOACs. In this study, only 60% of patients received on-label dosing and approximately 40% received under-dosed NOACs. However, patients treated with on-label NOACs showed a lower risk of TE and major bleeding events than those observed with warfarin use suggesting that on-label use of NOACs would be effective and safe in octogenarian patients. Furthermore, reduced off-label doses (underdosing), does not guarantee a lower risk of bleeding events in patients at a very advanced age. Therefore, labeled prescription of NOAC would be recommended in octogenarian patients with AF.

The clinical outcomes of the present study were influenced by several factors. Firstly, in this study, patients belonging to the NOACs group showed significantly higher CHADS_2 and CHA_2DS_2-VASc scores, which means their risk of developing TE events was higher with the use of NOACs. In univariate analysis, the effectiveness and safety outcomes were not significantly different between the groups. After adjusting for possible confounders, NOACs when compared with warfarin were associated with a reduced risk of TE, major bleeding events, and all-cause death with the difference being statistically significant. Considering high comorbidities in octogenarian patients, NOACs would be preferred to more effectively prevent TE and reduce the risk of major bleeding events. Secondly, elderly patients using warfarin have difficulty with maintaining a high TTR. Previous studies demonstrated poor TTR among patients using warfarin to prevent stroke in Asians. That is because there were concerns of cerebral hemorrhage due to several reports describing that the incidence of hemorrhagic stroke was higher in Asians than in the western population. Additionally, the recommended target international normalized ratio (INR) in those aged >70 years is 1.6–2.6 in Japan; thus, a few clinicians in Korea tend to maintain the INR at values <2.0–3.0.

There are several limitations of the present study. First, this was a retrospective single-center study, thus the decision regarding the types and dose of anticoagulants used was not randomized. Therefore, residual confounding factors not adjusted for in the analysis could have affected our results. Furthermore, the reason why physicians had selected the underdosed NOAC is unclear. In ORBIT-AF II registry reporting that 9% of patients with AF had received off-label underdosed NOAC according to U.S labelling, the reason of underdosing is also unclear. We speculate that physicians seem to consider the risk of bleeding more important in these fragile patients, which resulted to increase number of patients with underdosing. Second, the
event rate was observed to be very low in the NOACs group; thus, the multivariate analysis
could be over-fitted. To mitigate this problem, we used the stepwise backward elimination
method to select factors for inclusion in the multivariate analysis and weighted Kaplan-Meier
analysis using IPTW. However, the problem of overfitting was not completely solved by this
statistical method, so the results of this study would be considered as suggestive. Although it
would be reasonable to compare the outcomes between the groups using propensity score
matching methods, the number of octogenarian patients was not adequate to perform this
analysis. Also, we included 3 NOACs in this study; however, the number of each NOAC was
not adequate for a comparison with warfarin respectively. Finally, the TTR in our warfarin
group was low as in previous papers in Asian patients.[29–31] A recent retrospective study
reported a mean TTR as 50% in Korean AF patients.[32] The poor TTR control in warfarin
group might have affected the patients’ worse outcomes. However, this result also supports the
clinical usefulness of NOACs in elderly patients.

Conclusion
In octogenarian patients with AF, NOACs showed better outcomes in reducing the risk of TE,
major bleeding events, and all-cause deaths when compared with warfarin. Although most
patients had been prescribed a reduced dose, on-label use of NOACs was effective and safe in
this patient population. It would be reasonable to prescribe NOACs rather than warfarin in
octogenarian patients with non-valvular AF.

Supporting information
S1 Fig. Weighted Kaplan-Meier with use of inverse probability weighting.
(TIF)
S1 Table. Dosing criteria of NOACs.
(DOCX)
S2 Table. Multivariable analysis.
(DOCX)
S3 Table. Data adjusted with the use of inverse probability weighting.
(DOCX)
S4 Table. Baseline characteristics according to doses of NOACs.
(DOCX)

Author Contributions
Conceptualization: Hyue Mee Kim, Eue-Keun Choi.
Data curation: Hyue Mee Kim, Chan Soon Park, Myung-Jin Cha, Seo-Young Lee, Joon-
Myung Kwon.
Formal analysis: Hyue Mee Kim, Chan Soon Park, Myung-Jin Cha, Seo-Young Lee, Joon-
Myung Kwon.
Funding acquisition: Eue-Keun Choi.
Investigation: Hyue Mee Kim, Chan Soon Park, Myung-Jin Cha, Seil Oh.
Methodology: Hyue Mee Kim, Eue-Keun Choi, Seo-Young Lee, Joon-Myung Kwon.
Project administration: Hyue Mee Kim, Chan Soon Park, Myung-Jin Cha.
Resources: Hyue Mee Kim, Chan Soon Park, Myung-Jin Cha, Seil Oh.
Software: Hyue Mee Kim, Chan Soon Park, Myung-Jin Cha.
Supervision: Eue-Keun Choi.
Validation: Hyue Mee Kim, Myung-Jin Cha, Seo-Young Lee, Joon-Myung Kwon, Seil Oh.
Visualization: Hyue Mee Kim, Eue-Keun Choi.
Writing – original draft: Hyue Mee Kim.
Writing – review & editing: Eue-Keun Choi, Chan Soon Park, Myung-Jin Cha, Seo-Young Lee, Joon-Myung Kwon, Seil Oh.

References
1. Lee SR, Choi EK, Han KD, Cha MJ, Oh S. Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population. Int J Cardiol. 2017; 236:226–231. https://doi.org/10.1016/j.ijcard.2017.02.039 PMID: 28233629
2. Son MK, Lim NK, Cho MC, Park HY. Incidence and Risk Factors for Atrial Fibrillation in Korea: the National Health Insurance Service Database (2002–2010). Korean Circ J. 2016; 46(4):515–521. https://doi.org/10.4070/kcj.2016.46.4.515 PMID: 27482260
3. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009; 40(4):1410–1416. https://doi.org/10.1161/STROKEAHA.108.526988 PMID: 19182090
4. Lip GY, Clementy N, Pericart L, Banerjee A, Fauchier L. Stroke and major bleeding risk in elderly patients aged ≥ 75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke. 2015; 46(1):143–150. https://doi.org/10.1161/STROKEAHA.114.007199 PMID: 25424474
5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857–867. PMID: 17577005
6. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev: 2005;(3).CD001927. https://doi.org/10.1002/14651858.CD001927.pub2 PMID: 16034869
7. Monte S, Macchia A, Pellegrini F, Romero V, D’Ettorre A, et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J. 2006; 27(18):2217–2223. https://doi.org/10.1093/eurheartj/ehl208 PMID: 16935869
8. Bajorek BV, Krass I, Ogie SJ, Duguid MJ, Shenfield GM. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J Am Geriatr Soc. 2005; 53(11):1912–1920. https://doi.org/10.1111/j.1532-5415.2005.53564.x PMID: 16274372
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561 PMID: 19717844
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883–891. https://doi.org/10.1056/NEJMoa1107039 PMID: 21870978
11. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981–992. https://doi.org/10.1056/NEJMoa1107039 PMID: 21870978
12. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093–2104. https://doi.org/10.1056/NEJMoa1310907 PMID: 24251359
13. Cha MJ, Choi EK, Han KD, Lee SR, Lim WH, Oh S, et al. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation. Stroke. 2017; 48(11):3040–3048. https://doi.org/10.1161/STROKEAHA.117.018773 PMID: 28974629
14. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendrixsen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145(4):247–254. PMID: 16903915
15. Rosendaal FR, Cannegieter SC, van der Meer FJ, Brix E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69(3):236–239. PMID: 8470047
16. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation. 2015; 131(2):157–164. https://doi.org/10.1161/CIRCULATIONAHA.114.012061 PMID: 25359164

17. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014; 35(28):1864–1872. https://doi.org/10.1093/eurheartj/ehu046 PMID: 24561548

18. Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with non-vitamin K antagonist oral anticoagulants or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace. 2017. https://doi.org/10.1093/europace/euw416 PMID: 28177459

19. Kwon CH, Kim M, Kim J, Nam GB, Choi KJ, Kim YH. Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation. J Geriatr Cardiol. 2016; 13(7):566–572. https://doi.org/10.11190/j.issn.1671-5411.2016.07.011 PMID: 27605936

20. Chan PH, Huang D, Hai JJ, Li WH, Yin LX, Chan EW, et al. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. Heart Rhythm. 2016; 13(2):366–373. https://doi.org/10.1016/j.hrthm.2015.09.015 PMID: 26392326

21. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnyagina Y, Patel MR, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014; 130(2):138–146. https://doi.org/10.1161/CIRCULATIONAHA.113.005008 PMID: 24895454

22. Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014; 62(5):857–864. https://doi.org/10.1111/jgs.12799 PMID: 24786913

23. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123(21):2363–2372. https://doi.org/10.1161/CIRCULATIONAHA.110.004747 PMID: 21576658

24. Ho CW, Ho MH, Chan PH, Hai JJ, Cheung E, Yeung CY, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke. 2015; 46(1):23–30. https://doi.org/10.1161/STROKEAHA.110.006476 PMID: 25406148

25. Li WH, Huang D, Chiang CE, Lau CP, Tse HF, Chan EW, et al. Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project. Clin Cardiol. 2017; 40(4):222–229. https://doi.org/10.1002/clc.22649 PMID: 27893153

26. Yang QD, Niu Q, Zhou YH, Liu YH, Xu HW, Gu WP, et al. Incidence of cerebral hemorrhage in the Changsha community. A prospective study from 1986 to 2000. Cerebrovasc Dis. 2004; 17(4):303–313. https://doi.org/10.1159/000077341 PMID: 15026613

27. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, et al. Proportion of different subtypes of stroke in China. Stroke 2003; 34(9):2091–2096. https://doi.org/10.1161/01.STR.0000087149.42294.8C PMID: 12907817

28. Group JCSJW. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). Circ J. 2014; 78(8):1997–2021. PMID: 24965079

29. Oh S, Goto S, Accetta G, Angchaisukseri P, Camm AJ, Cools F, et al. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. Int J Cardiol 2016; 223:543–547. https://doi.org/10.1016/j.ijcard.2016.08.236 PMID: 27552578

30. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnyagina Y, Pan G, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013; 2(1):e000067. https://doi.org/10.1161/JAHA.112.000067 PMID: 23525418

31. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014; 111(5):789–797. https://doi.org/10.1160/TH13-11-0948 PMID: 24500243

32. Hong KS, Kim YK, Bae HJ, Nam HS, Kwon SU, Bang OY, et al. Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior Stroke: A Multicenter Retrospective Observational Study. J Clin Neurol. 2017; 13(3):273–280. https://doi.org/10.3988/jcn.2017.13.3.273 PMID: 28748679